United Therapeutics is trading 4.1% lower at $548.07 after consecutive sharp gains; available reporting has not identified a new company-specific catalyst for the October 2 decline. - On September 30, a Delaware court found Liquidia’s Yutrepia infringed two United Therapeutics patent claims, strengthening Tyvaso’s legal protections and driving the prior rally. - BTIG upgraded the stock on October 1. The broader market was sharply higher on October 2 after weak payroll data eased rate-hike concerns.